![Two Treatment Approaches for Human Regular U-500 Insulin in Patients With Type 2 Diabetes not Achieving Adequate Glycemic Control on High-Dose U-100 Insulin Therapy With or Without Oral Agents: A Randomized, Titration-To-Target Two Treatment Approaches for Human Regular U-500 Insulin in Patients With Type 2 Diabetes not Achieving Adequate Glycemic Control on High-Dose U-100 Insulin Therapy With or Without Oral Agents: A Randomized, Titration-To-Target](https://www.endocrinepractice.org/cms/attachment/ced59f52-d44f-48cd-8ab6-f9d04ff64f12/gr1.jpg)
Two Treatment Approaches for Human Regular U-500 Insulin in Patients With Type 2 Diabetes not Achieving Adequate Glycemic Control on High-Dose U-100 Insulin Therapy With or Without Oral Agents: A Randomized, Titration-To-Target
![Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis | Critical Care | Full Text Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis | Critical Care | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13054-021-03568-8/MediaObjects/13054_2021_3568_Fig2_HTML.png)
Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis | Critical Care | Full Text
![GALACTIC-HF: Omecamtiv mecarbil in patients with heart failure with reduced ejection fraction — NERDCAT GALACTIC-HF: Omecamtiv mecarbil in patients with heart failure with reduced ejection fraction — NERDCAT](https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1605560030307-YP3S98EPKQ9K83UJUS9C/image-asset.png?format=1000w)
GALACTIC-HF: Omecamtiv mecarbil in patients with heart failure with reduced ejection fraction — NERDCAT
Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria | PLOS ONE
![Patient flow diagram. BID, twice daily; PK, pharmacokinetics; QD, once... | Download Scientific Diagram Patient flow diagram. BID, twice daily; PK, pharmacokinetics; QD, once... | Download Scientific Diagram](https://www.researchgate.net/publication/325372028/figure/fig1/AS:630331015172096@1527294033000/Patient-flow-diagram-BID-twice-daily-PK-pharmacokinetics-QD-once-daily.png)
Patient flow diagram. BID, twice daily; PK, pharmacokinetics; QD, once... | Download Scientific Diagram
![Dosage Calculations The elements of the prescription can be curtailed down to several elements Dose is the amount of drug taken at one time Q is a variable. - ppt video online Dosage Calculations The elements of the prescription can be curtailed down to several elements Dose is the amount of drug taken at one time Q is a variable. - ppt video online](https://slideplayer.com/slide/9379680/28/images/3/Example+Two+i.e.+Timoptic%C2%AE+sig%3A+instill+1+gtt+OU+BID.+Dispense+5+ml+ophthalmic+container.+What+is+the+day+supply.jpg)
Dosage Calculations The elements of the prescription can be curtailed down to several elements Dose is the amount of drug taken at one time Q is a variable. - ppt video online
![Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers - John S. Grundy, Christopher D. King, Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers - John S. Grundy, Christopher D. King,](https://journals.sagepub.com/cms/10.1177/2045894020922814/asset/images/large/10.1177_2045894020922814-fig2.jpeg)
Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers - John S. Grundy, Christopher D. King,
![Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsrep31838/MediaObjects/41598_2016_Article_BFsrep31838_Fig1_HTML.jpg)
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports
![Pharmaceutics | Free Full-Text | Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation Pharmaceutics | Free Full-Text | Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-01489/article_deploy/html/images/pharmaceutics-13-01489-g001.png)
Pharmaceutics | Free Full-Text | Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
![Jessica Cataldi MD on Twitter: "For most infections, recommend TID amoxicillin dosing. Exceptions: otitis and strep pharyngitis. #COPedsID2020 https://t.co/MTHs8F1SLZ" / Twitter Jessica Cataldi MD on Twitter: "For most infections, recommend TID amoxicillin dosing. Exceptions: otitis and strep pharyngitis. #COPedsID2020 https://t.co/MTHs8F1SLZ" / Twitter](https://pbs.twimg.com/media/EmjgseOVgAAWYgL.jpg)
Jessica Cataldi MD on Twitter: "For most infections, recommend TID amoxicillin dosing. Exceptions: otitis and strep pharyngitis. #COPedsID2020 https://t.co/MTHs8F1SLZ" / Twitter
![Safety and Efficacy of Prophylactic Valganciclovir Dosing after Solid Organ Transplant - ATC Abstracts Safety and Efficacy of Prophylactic Valganciclovir Dosing after Solid Organ Transplant - ATC Abstracts](https://atcmeetingabstracts.com/wp-content/uploads/2020/05/g5339_1.png)
Safety and Efficacy of Prophylactic Valganciclovir Dosing after Solid Organ Transplant - ATC Abstracts
![Efficacy and Safety of Once-Daily (QD) Compared with Twice-Daily (BID) Maraviroc plus Optimized Background Therapy (OBT) in treatment-experienced Patients Infected with CCR5-tropic HIV-1: 24-week Combined Analysis of the MOTIVATE 1 & 2 Efficacy and Safety of Once-Daily (QD) Compared with Twice-Daily (BID) Maraviroc plus Optimized Background Therapy (OBT) in treatment-experienced Patients Infected with CCR5-tropic HIV-1: 24-week Combined Analysis of the MOTIVATE 1 & 2](https://www.natap.org/2007/images/073107/events-5.gif)